The Lipid Asset Is Unbalanced in Peripheral Nerve Sheath Tumors
Abstract
:1. Introduction
2. Results
2.1. Clinical Features of the PNST Patients’ Cohort
2.2. Untargeted Lipidomics of PNSTs
2.3. Targeted Sphingolipidomic Analysis of PNSTs
3. Discussion
4. Materials and Methods
4.1. Patient and Surgical Protocol
4.2. Lipidomic Analysis on Tumors and Control Tissues
4.2.1. Untargeted Lipidomics
4.2.2. Targeted Sphingolipidomics
4.3. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
References
- Guha, D.; Davidson, B.; Nadi, M.; Alotaibi, N.M.; Fehlings, M.G.; Gentili, F.; Valiante, T.A.; Tator, C.H.; Tymianski, M.; Guha, A.; et al. Management of peripheral nerve sheath tumors: 17 years of experience at Toronto Western Hospital. J. Neurosurg. 2018, 128, 1226–1234. [Google Scholar] [CrossRef] [PubMed]
- Louis, D.N.; Perry, A.; Wesseling, P.; Brat, D.J.; Cree, I.A.; Figarella-Branger, D.; Hawkins, C.; Ng, H.K.; Pfister, S.M.; Reifenberger, G.; et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro-Oncology 2021, 23, 1231–1251. [Google Scholar] [CrossRef]
- Kim, D.H.; Murovic, J.A.; Tiel, R.L.; Moes, G.; Kline, D.G. A series of 397 peripheral neural sheath tumors: 30-Year experience at Louisiana State University Health Sciences Center. J. Neurosurg. 2005, 102, 246–255. [Google Scholar] [CrossRef]
- Rodriguez, F.J.; Folpe, A.L.; Giannini, C.; Perry, A. Pathology of peripheral nerve sheath tumors: Diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012, 123, 295–319. [Google Scholar] [CrossRef] [Green Version]
- Akshintala, S.; Baldwin, A.; Liewehr, D.J.; Goodwin, A.; Blakeley, J.O.; Gross, A.M.; Steinberg, S.M.; Dombi, E.; Widemann, B.C. Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: Growth analysis of plexiform neurofibromas and distinct nodular lesions. Neuro-Oncology 2020, 22, 1368–1378. [Google Scholar] [CrossRef]
- Prada, C.E.; Rangwala, F.A.; Martin, L.J.; Lovell, A.M.; Saal, H.M.; Schorry, E.K.; Hopkin, R.J. Pediatric plexiform neurofibromas: Impact on morbidity and mortality in neurofibromatosis type 1. J. Pediatr. 2012, 160, 461–467. [Google Scholar] [CrossRef]
- Nguyen, R.; Kluwe, L.; Fuensterer, C.; Kentsch, M.; Friedrich, R.E.; Mautner, V.-F. Plexiform neurofibromas in children with neurofibromatosis type 1: Frequency and associated clinical deficits. J. Pediatr. 2011, 159, 652–655.e2. [Google Scholar] [CrossRef]
- Tidyman, W.E.; Rauen, K.A. The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation. Curr. Opin. Genet. Dev. 2009, 19, 230–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brems, H.; Beert, E.; de Ravel, T.; Legius, E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009, 10, 508–515. [Google Scholar] [CrossRef]
- Ferner, R.E. Neurofibromatosis 1 and neurofibromatosis 2: A twenty first century perspective. Lancet Neurol. 2007, 6, 340–351. [Google Scholar] [CrossRef]
- Kretschmer, T.; Antoniadis, G.; Heinen, C.; Börm, W.; Scheller, C.; Richter, H.-P.; Koenig, R.W. Nerve sheath tumor surgery: Case-guided discussion of ambiguous findings, appropriateness of removal, repeated surgery, and nerve repairs. Neurosurg. Focus 2007, 22, E19. [Google Scholar] [CrossRef] [Green Version]
- Montano, N.; D’Alessandris, Q.G.; D’Ercole, M.; Lauretti, L.; Pallini, R.; Di Bonaventura, R.; La Rocca, G.; Bianchi, F.; Fernandez, E. Tumors of the peripheral nervous system: Analysis of prognostic factors in a series with long-term follow-up and review of the literature. J. Neurosurg. 2016, 125, 363–371. [Google Scholar] [CrossRef] [Green Version]
- Vetrano, I.G.; Lucarella, F.; Dalolio, M.; Di Cristofori, A.; Nataloni, I.F.; Tiberio, F.; Gaini, S.M.; Grimoldi, N. The importance of predicting factors in the surgical outcome of peripheral nerve sheath tumors. J. Neurol. Surg. Part A Cent. Eur. Neurosurg. 2014, 75, 104–109. [Google Scholar] [CrossRef]
- Young, E.D.; Ingram, D.; Metcalf-Doetsch, W.; Khan, D.; Al Sannaa, G.; Le Loarer, F.; Lazar, A.J.F.; Slopis, J.; Torres, K.E.; Lev, D.; et al. Clinicopathological variables of sporadic schwannomas of peripheral nerve in 291 patients and expression of biologically relevant markers. J. Neurosurg. 2018, 129, 805–814. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vetrano, I.G.; Acerbi, F.; Falco, J.; Devigili, G.; Rinaldo, S.; Messina, G.; Prada, F.; D’Ammando, A.; Nazzi, V. Fluorescein-guided removal of peripheral nerve sheath tumors: A preliminary analysis of 20 cases. J. Neurosurg. 2019, 134, 260–269. [Google Scholar] [CrossRef] [PubMed]
- Vetrano, I.G.; Saletti, V.; Nazzi, V. Fluorescein-guided resection of plexiform neurofibromas: How I do it. Acta Neurochir. 2019, 161, 2141–2145. [Google Scholar] [CrossRef]
- Hirbe, A.C.; Gutmann, D.H. Neurofibromatosis type 1: A multidisciplinary approach to care. Lancet Neurol. 2014, 13, 834–843. [Google Scholar] [CrossRef] [Green Version]
- Martin, E.; Pendleton, C.; Verhoef, C.; Spinner, R.J.; Coert, J.H. Morbidity and Function Loss after Resection of Malignant Peripheral Nerve Sheath Tumors. Neurosurgery 2021, 93, 342. [Google Scholar] [CrossRef]
- Tucker, T.; Wolkenstein, P.; Revuz, J.; Zeller, J.; Friedman, J.M. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 2005, 65, 205–211. [Google Scholar] [CrossRef]
- Higham, C.S.; Dombi, E.; Rogiers, A.; Bhaumik, S.; Pans, S.; Connor, S.E.J.; Miettinen, M.; Sciot, R.; Tirabosco, R.; Brems, H.; et al. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro-Oncology 2018, 20, 818–825. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carrió, M.; Gel, B.; Terribas, E.; Zucchiatti, A.C.; Moliné, T.; Rosas, I.; Teulé, Á.; Cajal, S.R.Y.; López-Gutiérrez, J.C.; Blanco, I.; et al. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings. Hum. Mutat. 2018, 39, 1112–1125. [Google Scholar] [CrossRef]
- Staser, K.; Yang, F.-C.; Clapp, D.W. Pathogenesis of plexiform neurofibroma: Tumor-stromal/hematopoietic interactions in tumor progression. Annu. Rev. Pathol. 2012, 7, 469–495. [Google Scholar] [CrossRef] [Green Version]
- La Corte, E.; Dei Cas, M.; Raggi, A.; Patanè, M.; Broggi, M.; Schiavolin, S.; Calatozzolo, C.; Pollo, B.; Pipolo, C.; Bruzzone, M.G.; et al. Long and Very-Long-Chain Ceramides Correlate with A More Aggressive Behavior in Skull Base Chordoma Patients. Int. J. Mol. Sci. 2019, 20, 4480. [Google Scholar] [CrossRef] [Green Version]
- Santos, C.R.; Schulze, A. Lipid metabolism in cancer. FEBS J. 2012, 279, 2610–2623. [Google Scholar] [CrossRef]
- Low, J.-Y.; Brennen, W.N.; Meeker, A.K.; Ikonen, E.; Simons, B.W.; Laiho, M. Stromal CAVIN1 controls prostate cancer microenvironment and metastasis by modulating lipid distribution and inflammatory signaling. Mol. Cancer Res. 2020, 18, 1414–1426. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z.; Jiang, Q.; Dong, C. Metabolic reprogramming in triple-negative breast cancer. Cancer Biol. Med. 2020, 17, 44–59. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Hinz, S.; Uckermann, O.; Hönscheid, P.; von Schönfels, W.; Burmeister, G.; Hendricks, A.; Ackerman, J.M.; Baretton, G.B.; Hampe, J.; et al. Shotgun lipidomics-based characterization of the landscape of lipid metabolism in colorectal cancer. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2020, 1865, 158579. [Google Scholar] [CrossRef]
- Qin, C.; Yang, G.; Yang, J.; Ren, B.; Wang, H.; Chen, G.; Zhao, F.; You, L.; Wang, W.; Zhao, Y. Metabolism of pancreatic cancer: Paving the way to better anticancer strategies. Mol. Cancer 2020, 19, 50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mitchell, J.M.; Flight, R.M.; Moseley, H.N.B. Untargeted Lipidomics of Non-Small Cell Lung Carcinoma Demonstrates Differentially Abundant Lipid Classes in Cancer vs. Non-Cancer Tissue. Metabolites 2021, 11, 740. [Google Scholar] [CrossRef]
- Chen, Z.; Song, S.; Yang, C.; Dai, Z.; Gao, Y.; Li, N.; Zhu, J.; Mao, W.; Liu, J. Lipid profiling in malignant mesothelioma reveals promising signatures for diagnosis and prognosis: A plasma-based LC-MS lipidomics study. Clin. Chim. Acta 2021, 524, 34–42. [Google Scholar] [CrossRef]
- Jiang, M.; Li, C.; Liu, Q.; Wang, A.; Lei, M. Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats with Non-alcoholic Fatty Liver Disease. Front. Endocrinol. 2019, 10, 665. [Google Scholar] [CrossRef] [PubMed]
- Mingione, A.; Dei Cas, M.; Bonezzi, F.; Caretti, A.; Piccoli, M.; Anastasia, L.; Ghidoni, R.; Paroni, R.; Signorelli, P. Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis. Cell. Physiol. Biochem. 2020, 54, 110–125. [Google Scholar] [CrossRef] [PubMed]
- Dei Cas, M.; Zulueta, A.; Mingione, A.; Caretti, A.; Ghidoni, R.; Signorelli, P.; Paroni, R. An Innovative Lipidomic Workflow to Investigate the Lipid Profile in a Cystic Fibrosis Cell Line. Cells 2020, 9, 1197. [Google Scholar] [CrossRef]
- Hartmann, D.; Lucks, J.; Fuchs, S.; Schiffmann, S.; Schreiber, Y.; Ferreirós, N.; Merkens, J.; Marschalek, R.; Geisslinger, G.; Grösch, S. Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. Int. J. Biochem. Cell Biol. 2012, 44, 620–628. [Google Scholar] [CrossRef]
- Testai, L.; Martelli, A.; Flori, L.; Cicero, A.F.G.; Colletti, A. Coenzyme Q(10): Clinical Applications beyond Cardiovascular Diseases. Nutrients 2021, 13, 1697. [Google Scholar] [CrossRef]
- Zhang, K.; Lin, J.-W.; Wang, J.; Wu, X.; Gao, H.; Hsieh, Y.-C.; Hwu, P.; Liu, Y.-R.; Su, L.; Chiou, H.-Y.; et al. A germline missense mutation in COQ6 is associated with susceptibility to familial schwannomatosis. Genet. Med. 2014, 16, 787–792. [Google Scholar] [CrossRef]
- Cai, J.; Li, L.; Song, Y.; Xu, L.; Mao, Y.; Wang, H. Neuroprotective Effect of Brimonidine against Facial Nerve Crush Injury in Rats via Suppressing GFAP/PAF Activation and Neuroinflammation. ORL J. Otorhinolaryngol. Relat. Spec. 2021, 83, 449–456. [Google Scholar] [CrossRef]
- Zhang, Y.; Long, J.; Ren, J.; Huang, X.; Zhong, P.; Wang, B. Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects. Front. Oncol. 2021, 11, 731441. [Google Scholar] [CrossRef] [PubMed]
- Taurone, S.; Bianchi, E.; Attanasio, G.; Di Gioia, C.; Ierinó, R.; Carubbi, C.; Galli, D.; Pastore, F.S.; Giangaspero, F.; Filipo, R.; et al. Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue. Mol. Med. Rep. 2015, 12, 737–745. [Google Scholar] [CrossRef] [Green Version]
- Kohoutková, M.; Korimová, A.; Brázda, V.; Kohoutek, J.; Dubový, P. Early inflammatory profiling of schwannoma cells induced by lipopolysaccharide. Histochem. Cell Biol. 2017, 148, 607–615. [Google Scholar] [CrossRef]
- Boerboom, A.; Dion, V.; Chariot, A.; Franzen, R. Molecular Mechanisms Involved in Schwann Cell Plasticity. Front. Mol. Neurosci. 2017, 10, 38. [Google Scholar] [CrossRef] [Green Version]
- Dean, J.M.; Lodhi, I.J. Structural and functional roles of ether lipids. Protein Cell 2018, 9, 196–206. [Google Scholar] [CrossRef] [PubMed]
- Luoma, A.M.; Kuo, F.; Cakici, O.; Crowther, M.N.; Denninger, A.R.; Avila, R.L.; Brites, P.; Kirschner, D.A. Plasmalogen phospholipids protect internodal myelin from oxidative damage. Free Radic. Biol. Med. 2015, 84, 296–310. [Google Scholar] [CrossRef]
- Schmitt, S.; Castelvetri, L.C.; Simons, M. Metabolism and functions of lipids in myelin. Biochim. Biophys. Acta 2015, 1851, 999–1005. [Google Scholar] [CrossRef] [PubMed]
- da Silva, T.F.; Eira, J.; Lopes, A.T.; Malheiro, A.R.; Sousa, V.; Luoma, A.; Avila, R.L.; Wanders, R.J.A.; Just, W.W.; Kirschner, D.A.; et al. Peripheral nervous system plasmalogens regulate Schwann cell differentiation and myelination. J. Clin. Investig. 2014, 124, 2560–2570. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiménez-Rojo, N.; Riezman, H. On the road to unraveling the molecular functions of ether lipids. FEBS Lett. 2019, 593, 2378–2389. [Google Scholar] [CrossRef] [Green Version]
- Canals, D.; Salamone, S.; Hannun, Y.A. Visualizing bioactive ceramides. Chem. Phys. Lipids 2018, 216, 142–151. [Google Scholar] [CrossRef]
- Al-Rashed, F.; Ahmad, Z.; Snider, A.J.; Thomas, R.; Kochumon, S.; Melhem, M.; Sindhu, S.; Obeid, L.M.; Al-Mulla, F.; Hannun, Y.A.; et al. Ceramide kinase regulates TNF-α-induced immune responses in human monocytic cells. Sci. Rep. 2021, 11, 8259. [Google Scholar] [CrossRef]
- Ponnusamy, S.; Meyers-Needham, M.; Senkal, C.E.; Saddoughi, S.A.; Sentelle, D.; Selvam, S.P.; Salas, A.; Ogretmen, B. Sphingolipids and cancer: Ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol. 2010, 6, 1603–1624. [Google Scholar] [CrossRef] [Green Version]
- Somenzi, G.; Sala, G.; Rossetti, S.; Ren, M.; Ghidoni, R.; Sacchi, N. Disruption of retinoic acid receptor alpha reveals the growth promoter face of retinoic acid. PLoS ONE 2007, 2, e836. [Google Scholar] [CrossRef] [PubMed]
- Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016, 131, 803–820. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hanemann, C.O.; Blakeley, J.O.; Nunes, F.P.; Robertson, K.; Stemmer-Rachamimov, A.; Mautner, V.; Kurtz, A.; Ferguson, M.; Widemann, B.C.; Evans, D.G.; et al. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology 2016, 87, S40–S48. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Burrello, J.; Biemmi, V.; Dei Cas, M.; Amongero, M.; Bolis, S.; Lazzarini, E.; Bollini, S.; Vassalli, G.; Paroni, R.; Barile, L. Sphingolipid composition of circulating extracellular vesicles after myocardial ischemia. Sci. Rep. 2020, 10, 16182. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vetrano, I.G.; Dei Cas, M.; Nazzi, V.; Eoli, M.; Innocenti, N.; Saletti, V.; Potenza, A.; Carrozzini, T.; Pollaci, G.; Gorla, G.; et al. The Lipid Asset Is Unbalanced in Peripheral Nerve Sheath Tumors. Int. J. Mol. Sci. 2022, 23, 61. https://doi.org/10.3390/ijms23010061
Vetrano IG, Dei Cas M, Nazzi V, Eoli M, Innocenti N, Saletti V, Potenza A, Carrozzini T, Pollaci G, Gorla G, et al. The Lipid Asset Is Unbalanced in Peripheral Nerve Sheath Tumors. International Journal of Molecular Sciences. 2022; 23(1):61. https://doi.org/10.3390/ijms23010061
Chicago/Turabian StyleVetrano, Ignazio G., Michele Dei Cas, Vittoria Nazzi, Marica Eoli, Niccolò Innocenti, Veronica Saletti, Antonella Potenza, Tatiana Carrozzini, Giuliana Pollaci, Gemma Gorla, and et al. 2022. "The Lipid Asset Is Unbalanced in Peripheral Nerve Sheath Tumors" International Journal of Molecular Sciences 23, no. 1: 61. https://doi.org/10.3390/ijms23010061